University College London

Hedera to host five days of events at Davos 2023 with POLITICO, will.i.am, Starling Labs, IBM, and more

Retrieved on: 
Tuesday, January 10, 2023
DOVU, University College London, WEF, Communication, Ministry, Volkswagen Group, Climate, Esplanade, Davos Congress Centre, AY, ID, ESG, ServiceNow, Piper, VP Bank, FX, Policy, World Economic Forum, Black Eyed Peas, Carbon, SVP, Digital transformation, Health equity, Innovation, MIT, Standard Bank, McDowell, IBM, EV, Avery Dennison, Africa House, Movement, Pea, POLITICO, Council, DLT, Electricity, Heart, DLA Piper, Principal, Risk management, Nightclub, Tourism, Management, Hedera

DAVOS, Switzerland, Jan. 10, 2023 /PRNewswire/ -- Hedera, the most innovative, sustainable, enterprise-grade public network for the decentralized economy, has announced the agenda for Hedera Haus at Davos 2023, coinciding with this year's World Economic Forum (WEF). Hedera Haus — Hedera's unique exhibition space at the heart of the action — will set up shop at Promenade 71, Davos Platz to host drinks receptions, insightful panel discussions, keynotes, and afterparties with critical players from the worlds of DLT and enterprise technology.

Key Points: 
  • The line-up of events at Hedera Haus includes a mix of exclusive, invitation-only proceedings, as well as panels, receptions, and parties, open to all attendees at Davos during the WEF 2023.
  • Hedera Haus is a carbon neutral venue, with Hedera having purchased carbon offsets through DOVU on Hedera to cover flights, electricity, recyclable materials and buildout, shipping, and food & beverage at the event.
  • Highlights from the Hedera Haus agenda include:
    Will.i.am is the founding and lead member of the musical group Black Eyed Peas.
  • It outlines the panels, content, lunches, cocktail receptions, and other events that will be taking place at Hedera Haus this year.

Becker Welcomes Corporate Shareholder Gabriel Monzon-Cortarelli in New York

Retrieved on: 
Tuesday, January 10, 2023
Fordham University School of Law, United, Melinda Haag, Transport, Food, LL.B, SDA Bocconi School of Management, Orrick, Becker, American International, United Kingdom, Engineering, Becker's, University College London, Private investigator, Security (finance), Financial services, European

Mr. Monzon-Cortarelli was most recently a partner at Orrick, Herrington & Sutcliffe LLP and will be based in New York and Milan.

Key Points: 
  • Mr. Monzon-Cortarelli was most recently a partner at Orrick, Herrington & Sutcliffe LLP and will be based in New York and Milan.
  • Becker's Managing Shareholder and CEO Gary Rosen said, "The firm is delighted to welcome Gabriel and his international, entrepreneurial approach to business.
  • Becker's New York Regional Managing Shareholder Victor DiGioia added, "We are thrilled to gain a lawyer of Gabriel's caliber and background.
  • The firm provides sophisticated counsel on corporate and regulatory law, as well as on all aspects of litigation and dispute resolution.

Digitalis Ventures Appoints Misti Ushio as a Managing Partner

Retrieved on: 
Wednesday, January 4, 2023
General Health, Professional Services, Health, Finance, Partner (business rank), Doctor of Philosophy, Merck & Co., Merck, Biochemical engineering, Multimedia, Science, Acquisition, Patient, Columbia University, 180 Degree Capital, Digitalis, Johns Hopkins University, Vaccine, Chemical engineering, University College London, Management

Digitalis Ventures announced today that Misti Ushio, Ph.D. has joined the group as a Managing Partner.

Key Points: 
  • Digitalis Ventures announced today that Misti Ushio, Ph.D. has joined the group as a Managing Partner.
  • Dr. Ushio brings more than 25 years of leadership in venture capital, pharmaceuticals, and early-stage life science company building.
  • View the full release here: https://www.businesswire.com/news/home/20230104005342/en/
    Digitalis Ventures Founder and Managing Partner, Geoff Smith, stated, “We are delighted to welcome Misti to Digitalis Ventures as we continue to grow our global team with start-up, scale-up, and governance expertise in company building.
  • Misti brings a wealth of leadership and scientific experience to the group and, as a managing partner, she will lead in both firm strategy and investment portfolio management at Digitalis Ventures.”
    In October 2022, Digitalis Ventures closed its fourth fund totaling $300 million in commitments.

Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients

Retrieved on: 
Tuesday, January 3, 2023
Medical school, F2, Fatty liver disease, Fibrosis, Patient, CCL24, PSC, Communication, ELF, Optimism, NAFLD, Primary sclerosing cholangitis, Systemic scleroderma, Institute of Liver and Biliary Sciences, Sheila Sherlock, Cirrhosis, SC, University College London, Marketing, Division, Nature, Faculty, Safety, Inflammation, Clinical trial, CMMB, UCL, Scleroderma, Icahn School of Medicine at Mount Sinai, Intracellular digestion, Therapy, Principal, TEL, Gastroenterology, F3, Proning, Doctor of Philosophy, Risk, Pharmacokinetics, Non-alcoholic fatty liver disease, Liver, University College London Hospitals NHS Foundation Trust, Research, NASH, Biomarker, Hepatology, Medical imaging, Pharmaceutical industry, Vaccine, Medicine, COVID, MD

TEL AVIV, Israel, Jan. 3, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today reported top-line results from its Phase 2a trial assessing CM-101, its first-in-class CCL24-neutralizing monoclonal antibody, in non-alcoholic steatohepatitis (NASH) patients. The trial met its primary endpoint of safety and tolerability, and CM-101 achieved reductions in secondary endpoints that include a range of liver fibrosis biomarkers and physiologic assessments measured at baseline and at week 20.

Key Points: 
  • The randomized, placebo-controlled trial enrolled 23 NASH patients with stage F1c, F2 and F3 disease who were randomized to receive either CM-101 or placebo.
  • Dr. Pfost continued, "This is the third clinical trial in patients demonstrating the activity of CM-101 as measured by fibro-inflammatory biomarkers and physiological assessments.
  • A Phase 2 liver fibrosis biomarker study in NASH patients was recently completed and a Phase 2 trial in primary sclerosing cholangitis patients is ongoing.
  • Chemomab expects to begin enrolling patients in a Phase 2 trial in systemic sclerosis early in 2023.

MindBridge featured in the Vector Institute's top AI20 for 2023

Retrieved on: 
Tuesday, December 20, 2022
Organization, Vector, Holism, Montreal, AI Companies of India, Vector Institute, University College London, Risk, Bias, Multimedia, Publication, SAP, Government, World Economic Forum, Algorithm, Science, Research, ISO, Artificial intelligence, Intelligence, Machine learning, Medical device, Online shopping, AI

OTTAWA, ON, Dec. 20, 2022 /PRNewswire/ -- Financial risk discovery and anomaly detection software company MindBridge AI is thrilled to be included in the Vector Institute's inaugural AI20 for 2023 .

Key Points: 
  • OTTAWA, ON, Dec. 20, 2022 /PRNewswire/ -- Financial risk discovery and anomaly detection software company MindBridge AI is thrilled to be included in the Vector Institute's inaugural AI20 for 2023 .
  • "We have always been big believers in partnering with well-known, trusted organizations such as The Vector Institute to instill confidence in the value of AI and, by extension, MindBridge," said Robin Grosset, MindBridge's Chief Technology Officer.
  • MindBridge AI makes it easy for auditors and business professionals to find the unusual financial activity lurking within this data without requiring advanced analytical skills.
  • "AI-enabled science and machine learning used to be considered a nice-to-have in financial services," says MindBridge CEO Leyton Perris.

VERSES Publishes New Research Proposing Future Path for AI

Retrieved on: 
Wednesday, December 14, 2022
Intelligence, Information Age, University, Consultant, Research, Computer science, Renã A. S. Robinson, Artificiality, University of Konstanz, Deep learning, Artificial intelligence, University College London, IEEE Standards Association, Some Institutes for Advanced Study, Biomedical engineering, AGI, University of Oxford, Stony Brook University, Wellcome Centre for Human Neuroimaging, Human, ArXiv, IEEE, USD, Franck–Condon principle, AI, Automation, Brain, X-ray, Nature, Science, Ecosystem, Experimental psychology, Artificial general intelligence, Collective behavior, Department of Physics and Astronomy, University of Manchester, NEO, Astronomy, Medical device, Information technology, Physics

The paper, entitled “ Designing Ecosystems of Intelligence from First Principles ,” presents a vision and roadmap for AI based on a field of research called Active Inference.

Key Points: 
  • The paper, entitled “ Designing Ecosystems of Intelligence from First Principles ,” presents a vision and roadmap for AI based on a field of research called Active Inference.
  • KOSM, the network operating system from VERSES, uses the Active Inference framework as the foundation for its AI decision-making and planning capabilities.
  • The global AI market is projected to grow to USD $1.394 trillion by the end of the decade.
  • Despite its successful applications, AI has fundamental challenges impeding the ultimate aspiration of human (or super-human) level generalized machine intelligence.

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

Retrieved on: 
Monday, December 12, 2022
Follicular lymphoma, Annual report, Lymphatic system, Security (finance), Webcast, EHA, Phenotype, Tisagenlecleucel, CRS, ASH, Cure, B-ALL, Toxicity, Extranodal NK/T-cell lymphoma, nasal type, IQR, Lymphoma, COVID-19, CD22, Human, Acute leukemia, CAR, CNS, Lymphoid leukemia, Safety, CLL, Cancer, Bone marrow, University College London, B-cell lymphoma, T-cell lymphoma, Risk, MRD, Society, Peripheral T-cell lymphoma, ALL, UCL, Engineering, Doctor of Philosophy, ORR, Rate, NHL, TRBC1, Patient, Investigational New Drug, Cell, SCT, CD19, Toxic shock syndrome, Royal College of Pathologists, Blackstone, MCL, Therapy, Pharmaceutical industry, Vaccine, Medical device, MD, DLBCL

Importantly, we have not observed antigen negative relapse,” said Dr. Martin Pule, Chief Scientific Officer at Autolus.

Key Points: 
  • Importantly, we have not observed antigen negative relapse,” said Dr. Martin Pule, Chief Scientific Officer at Autolus.
  • “In the AUTO4 study, some patients have experienced durable metabolic CRs, including one patient up to the one-year mark.
  • A simultaneous audio webcast and replay will be accessible on the events section of Autolus website.
  • In collaboration with Autolus’ academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trials for B-NHL.

Ascension Healthcare Announces Positive Data from Phase 2 Study of XLR8 in Severe Haemophilia A Patients

Retrieved on: 
Monday, December 12, 2022
Haemophilia, Bleeding, Use, Prevalence, FDA, Factor VIII, University College London, Gold, VIII, PEGylation, Osteoarthritis, Coronavirus Scientific Advisory Board (Turkey), Fibrinolysis, Potency, Haemophilia A, History, Standard of care, XLR8, Risk, Male, Ascension, Patient, Vaccine, Pharmaceutical industry, Birth control

Haemophilia A patients lack sufficient factor VIII clotting factors which leaves them at risk of uncontrolled bleeding.

Key Points: 
  • Haemophilia A patients lack sufficient factor VIII clotting factors which leaves them at risk of uncontrolled bleeding.
  • This trial was designed to demonstrate that administration of PEGLip, following a normal dose of prophylactic, standard half-life FVIII in severe, non-inhibitor Haemophilia A patients can both enhance clotting activity and extend the dosing interval beyond FVIII administered alone.
  • Results from the study demonstrated that clotting activity was significantly improved at certain time points over baseline and over injection of FVIII alone.
  • The therapy is primarily aimed at f severe patients who are receiving standard of care prophylaxis with intravenous FVIII, where the adjuvant will extend their FVIII dosing interval, thereby improving compliance.

Ascension Healthcare Announces Positive Data from Phase 2 Study of SelectAte in Severe Haemophilia A Patients with inhibitors

Retrieved on: 
Monday, December 12, 2022
Haemophilia, Bleeding, Prevalence, Antibody, FDA, Factor VIII, University College London, VIII, Osteoarthritis, Coronavirus Scientific Advisory Board (Turkey), Fibrinolysis, Haemophilia A, History, Risk, Male, Selective serotonin reuptake inhibitor, Ascension, Patient, Pharmaceutical industry

SelectAte is a proprietary pre-mixed combination of a recombinant factor VIII clotting protein and PEGylated liposomes (PEGLip), co-injected intravenously.

Key Points: 
  • SelectAte is a proprietary pre-mixed combination of a recombinant factor VIII clotting protein and PEGylated liposomes (PEGLip), co-injected intravenously.
  • These results were achieved in both non-inhibitor patients and also those that were both inhibitor prone and presenting with low levels of inhibitors.
  • SelectAte is being developed to treat severe HA patients who have developed inhibitors (neutralising antibodies) to FVIII.
  • Approximately 30% of severe HA patients develop inhibitors to prophylactic FVIII replacement therapy, rendering such therapy ineffective.

Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences

Retrieved on: 
Thursday, December 8, 2022
BLA, Cell, CAR, Annual report, Lymphatic system, Partnership, ALL, Security (finance), FDA, UCL, Food, Lymphoid leukemia, Safety, Engineering, Cancer, Regulation of tobacco by the U.S. Food and Drug Administration, CD19, University College London, Biologics license application, CR, Acute lymphoblastic leukemia, Toxicity, Blackstone, Risk, MRD, Investment, Therapy, Senior, COVID-19, Patient, Pharmaceutical industry, Vaccine

The second Blackstone milestone of $35m is a pre-agreed manufacturing milestone as a result of completion of planned activities demonstrating the performance and qualification of Autolus’ obe-cel’s manufacturing process.

Key Points: 
  • The second Blackstone milestone of $35m is a pre-agreed manufacturing milestone as a result of completion of planned activities demonstrating the performance and qualification of Autolus’ obe-cel’s manufacturing process.
  • “Receiving these two $35m milestone payments highlights the continuing strength and collaborative nature of our partnership with Blackstone,” said Dr. Christian Itin, CEO of Autolus.
  • Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors.
  • By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives.